Student or educator? Sign up with your school email and get 6 months of Pro free.
PreprintCited by 179

The DOI matches its Crossref record.

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

Open access
Matsuyama, Shutoku, Kawase, Miyuki, Nao, Naganori, Shirato, Kazuya, Ujike, Makoto, Kamitani, Wataru, Shimojima, Masayuki, Fukushi, Shuetsu · 2020 · bioRxiv (Cold Spring Harbor Laboratory)

Abstract

Steroid compounds, which are expected to have dual functions in blocking host inflammation and MERS-CoV replication, were screened from a chemical library. Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus. The effective concentration of ciclesonide to block SARS-CoV-2 (the cause of COVID-19) replication (EC 90 ) was 6.3 μM. After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics. A recombinant virus with the mutation was also resistant to ciclesonide suppression of viral replication. These observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2020.03.11.987016

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 11

  1. 2020, Drug treatment options for the 2019-new coronavirus (2019-nCoV), Biosci. Trends A, 01020, 10
  2. M. Wang , et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2019–2021 (2020). · DOI · Paper page
  3. 2019, Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection□: A cohort study, 29, 48
  4. 10.1016/j.jcv.2004.07.006 · DOI · Paper page
  5. 10.3391/mbi.2017.8.1.01 · DOI · Paper page
  6. 10.1073/pnas.1618310114 · DOI · Paper page
  7. A. Lundin , et al., Targeting Membrane-Bound Viral RNA Synthesis Reveals Potent Inhibition of Diverse Coronaviruses Including the Middle East Respiratory Syndrome Virus. PLoS Pathog. 10(2014). · DOI
  8. 2017, MERS coronavirus nsp1 participates in an efficient propagation through a specific interaction with viral RNA, Virology, 511, 95, 10.1016/j.virol.2017.08.026 · DOI
  9. 2020, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Euro Surveill., 25, 1
  10. 2018, Structural and Biochemical Characterization of Endoribonuclease Nsp15 Encoded by Middle East Respiratory Syndrome Coronavirus, J. Virol., 92, 1
  11. 10.1128/JVI.01890-13 · DOI · Paper page

Cited by

See all 179

Metadata

Authors
Matsuyama, S., Kawase, M., Nao, N., Shirato, K., Ujike, M., Kamitani, W., Shimojima, M., & Fukushi, S.
Venue
bioRxiv (Cold Spring Harbor Laboratory)
Publisher
openRxiv
Published
2020-03-12
OpenAlex
W3012236996
Cited by
179
References
0
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. https://app.cochat.ai/papers/10.1101/2020.03.11.987016
The paper
Matsuyama, S., Kawase, M., Nao, N., Shirato, K., Ujike, M., Kamitani, W., Shimojima, M., & Fukushi, S. (2020). The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2020.03.11.987016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.